Lifang & Partners

Intellectual Property

Partner

Ms. Wang focuses her practice on patent and technology transaction areas. Ms. Wang had been working consecutively in LungTin IP firm, the Patent and Licensing Department of Novozymes China and later in AnJie Law Firm. She joined Lifang & Partners in June 2021.

Ms. Wang mainly works for high-tech companies, especially those in the fields of pharma, biotechnology, chemistry and chemical engineering. She represents clients in patent invalidation and infringement litigation. As a legal counsel to a number of biopharmaceutical companies, she helps the clients with patent strategy development, establishment of enterprise IP system, patent prosecution, and provides clients with patent validity analysis, FTO analysis, etc.

In the past few years, Ms. Wang has represented many domestic companies in the negotiation of technology licensing and R&D collaboration with foreign companies and universities, covering the fields of gene editing, drug development, medical devices, cosmetics, semi-conductor and other technical fields, and helped clients draft and review contracts.

In addition to China patent practice, Ms. Wang also has a deep understanding and practice in major foreign countries such as the United States, Europe and India, and can provide clients with a global perspective on patent protection strategies. During her nine years’ working period as an inhouse IP counsel, Ms. Wang had worked on global IP issues for several business units, including managing a series of European patent opposition and appeal cases between Novozymes and its competitors, and participating in licensing negotiations to settle Novozymes’ global IP disputes. Ms. Wang had also worked as a team member in a plenty of R&D projects, with rich experiences in patent landscape analysis, design around and IP risk management.

Chinese/English

- LLM, Temple University

- M.Sc. in Biochemistry, Tsinghua University

- B.Sc. in Biological Science and Biotechnology, Zhejiang University